In recent years, the intersection of neuroscience and psychiatry has been rapidly advancing, leading to transformative insights into the mechanisms underlying mental health disorders. A groundbreaking narrative review published in Translational Psychiatry in 2026 by Klumpp, Davey, and Langenecker provides an avant-garde exploration of neural predictors of treatment outcomes in internalizing disorders through the lens of emotion regulation. Their comprehensive synthesis signals a pivotal shift in understanding how brain-based biomarkers can forecast therapeutic efficacy, heralding a new epoch in precision psychiatry.
Internalizing disorders, encompassing conditions such as depression, anxiety, and related affective dysregulations, represent a substantial clinical challenge due to their heterogeneous presentations and variable responses to treatment. Traditionally, therapeutic approaches have relied heavily on symptomatology and behavioral assessments, which often offer limited predictive power about treatment success. This knowledge gap has driven researchers to probe the neural substrates involved in emotion regulation—the brain’s capacity to modulate affective states—to identify objective markers that could predict individual outcomes.
Central to this review is the discussion of brain circuits implicated in emotion regulation, including but not limited to the prefrontal cortex, amygdala, anterior cingulate cortex, and insula. These regions collectively orchestrate the appraisal, modulation, and expression of emotional experiences. Notably, neuroimaging studies employing functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) have illuminated patterns of activation and connectivity within these networks that correlate with symptom severity and responsiveness to pharmacological and psychotherapeutic interventions.
One of the key insights highlighted is the role of the dorsolateral prefrontal cortex (dlPFC) in exerting top-down control over limbic structures such as the amygdala. Enhanced dlPFC engagement during emotion regulation tasks has been associated with better treatment response, suggesting that efficient cognitive control mechanisms are crucial for clinical improvement. Conversely, hypoactivation in these control areas, or hyperreactivity in the amygdala, may predict resistance to traditional therapies, thereby urging the exploration of adjunctive treatments targeting these neural circuits more directly.
The review also underscores the promise of resting-state connectivity analyses, which evaluate the synchronization of brain activity patterns in the absence of task demands. Aberrant connectivity within the default mode network (DMN) and salience network has emerged as a hallmark of many internalizing disorders. Disruptions in these networks could hinder adaptive emotion regulation by impairing self-referential processing and the allocation of attention to salient emotional stimuli. Tracking these disruptions longitudinally offers a non-invasive window into treatment progress and potential relapse risk.
Importantly, Klumpp and colleagues emphasize the transdiagnostic value of neural markers in internalizing disorders. They argue that despite categorical distinctions between anxiety, depression, and related conditions, overlapping neurobiological signatures can predict common pathways to recovery. This perspective aligns with the Research Domain Criteria (RDoC) framework, promoting dimensional and mechanistic approaches over traditional diagnostic boundaries.
Another critical dimension explored in the paper relates to personalized medicine. The integration of neural predictors with clinical and demographic data creates a multifaceted profile that can guide individualized treatment plans. For instance, patients exhibiting specific patterns of brain activity might benefit more from cognitive-behavioral therapy focusing on cognitive reappraisal, while others might respond preferentially to pharmacotherapies targeting neurotransmitter systems connected to emotion regulation circuits.
Moreover, the authors shed light on emerging technologies poised to refine prediction models further. Machine learning algorithms trained on multimodal datasets—including neuroimaging, genetic, and behavioral metrics—have begun to identify complex patterns invisible to traditional statistical approaches. These tools hold the promise of enabling clinicians to anticipate treatment response with unprecedented accuracy, reducing trial-and-error periods that currently burden patients and healthcare systems.
The review also navigates the challenges inherent in translating these neuroscientific discoveries into clinical practice. Variability in imaging protocols, small sample sizes, and the heterogeneity of study populations limit the generalizability of findings. Klumpp et al. advocate for large-scale, multicenter collaborations with standardized methodologies to surmount these barriers and validate identified biomarkers robustly.
Emotion regulation itself is dissected not only as a therapeutic target but as a dynamic process influenced by developmental trajectories, environmental exposures, and genetic predispositions. The authors argue for longitudinal studies integrating these factors to unravel how they interact to shape neural function and treatment outcomes over time, thus informing early intervention strategies.
Additionally, the review highlights novel pharmacological agents and neuromodulation techniques, such as transcranial magnetic stimulation and deep brain stimulation, which modulate specific neural circuits implicated in emotion regulation. Understanding the neural signatures predictive of responsiveness to these advanced interventions could revolutionize treatment paradigms for refractory cases.
Crucially, the narrative synthesizes evidence that incorporating emotion regulation training into treatment regimens measurably enhances neural plasticity and clinical response. Interventions such as mindfulness-based stress reduction and emotion-focused therapies can realign dysfunctional neural circuitry, suggesting that neural markers might also serve as biomarkers for the mechanistic processes underlying therapeutic change.
Furthermore, Klumpp and colleagues stress the ethical considerations in deploying neuroimaging-derived predictors. The potential for stigmatization or misclassification necessitates rigorous safeguards, transparency in data interpretation, and equitable access to emerging diagnostic tools, ensuring that advances in neuroscience translate into societal benefit without unintended harm.
Advancing this field will require interdisciplinary collaboration melding psychiatry, neuroscience, data science, and bioethics. The authors call for an integrative research agenda that bridges basic and clinical science to establish neural predictors not only as prognostic tools but also as guides for novel, mechanism-based interventions tailored to individual neurobiological profiles.
This comprehensive review epitomizes the exciting frontier where neuroscience intersects with clinical psychiatry, illuminating how understanding the neural underpinnings of emotion regulation can transform treatment outcomes in internalizing disorders. By unmasking the brain’s predictive signals, the study lays the foundation for a future where mental health care is defined by precision, personalization, and profound scientific insight.
Subject of Research: Neural predictors of treatment outcome through emotion regulation in internalizing disorders
Article Title: Neural predictors of treatment outcome through emotion regulation in internalizing disorders: a narrative review
Article References:
Klumpp, H., Davey, D. & Langenecker, S.A. Neural predictors of treatment outcome through emotion regulation in internalizing disorders: a narrative review. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03908-8
Image Credits: AI Generated
